Victory Capital Management
VIR icon

Victory Capital Management’s Vir Biotechnology VIR Stock Holding History

Victory Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Buy
20,691
+3,002
+17% +$28.6K ﹤0.01% 2254
2026
Q1 		$158K Buy
17,689
+2,717
+18% +$21.6K ﹤0.01% 2223
2025
Q4 		$90.3K Buy
14,972
+201
+1% +$1.2K ﹤0.01% 2279
2025
Q3 		$84.3K Sell
14,771
-2,387
-14% -$12.2K ﹤0.01% 2310
2025
Q2 		$86.5K Sell
17,158
-155,695
-90% -$835K ﹤0.01% 2340
2025
Q1 		$1.12M Buy
172,853
+84,077
+95% +$748K ﹤0.01% 1749
2024
Q4 		$652K Buy
88,776
+7,507
+9% +$59.2K ﹤0.01% 1956
2024
Q3 		$609K Buy
81,269
+15,696
+24% +$136K ﹤0.01% 1957
2024
Q2 		$584K Buy
65,573
+19,216
+41% +$184K ﹤0.01% 1930
2024
Q1 		$470K Sell
46,357
-28,184
-38% -$287K ﹤0.01% 2002
2023
Q4 		$750K Sell
74,541
-48,489
-39% -$443K ﹤0.01% 1842
2023
Q3 		$1.15M Buy
123,030
+18,882
+18% +$269K ﹤0.01% 1583
2023
Q2 		$2.55M Buy
104,148
+6,769
+7% +$170K ﹤0.01% 1331
2023
Q1 		$2.27M Buy
97,379
+21,736
+29% +$556K ﹤0.01% 1366
2022
Q4 		$1.91M Buy
75,643
+58,852
+350% +$1.44M ﹤0.01% 1457
2022
Q3 		$324K Sell
16,791
-2,581
-13% -$65.6K ﹤0.01% 2223
2022
Q2 		$493K Sell
19,372
-1,173
-6% -$27.4K ﹤0.01% 2059
2022
Q1 		$418K Buy
20,545
+10,073
+96% +$299K ﹤0.01% 2190
2021
Q4 		$438K Buy
10,472
+284
+3% +$11.1K ﹤0.01% 2218
2021
Q3 		$443K Buy
10,188
+1,377
+16% +$59.6K ﹤0.01% 2229
2021
Q2 		$417K Buy
8,811
+296
+3% +$13.5K ﹤0.01% 2293
2021
Q1 		$437K Sell
8,515
-21
-0.2% -$1.13K ﹤0.01% 2257
2020
Q4 		$229K Sell
8,536
-1,362
-14% -$44.3K ﹤0.01% 2349
2020
Q3 		$340K Buy
9,898
+977
+11% +$42.1K ﹤0.01% 2116
2020
Q2 		$365K Buy
8,921
+1,891
+27% +$63.5K ﹤0.01% 2097
2020
Q1 		$241K Buy
+7,030
New +$189K ﹤0.01% 2095

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Victory Capital Management's VIR Position: Q2 2026 in Review

Victory Capital Management increased its Vir Biotechnology (VIR) stake by 17% in Q2 2026, buying an estimated $28.6K and bringing the position to 20,691 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

Victory Capital Management first reported a position in VIR in Q1 2020 and has held it in 26 quarters since. The position peaked at $2.55M in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Victory Capital Management held 20,691 shares of Vir Biotechnology worth $211K as of Q2 2026.
  • Victory Capital Management bought 3,002 Vir Biotechnology shares in Q2 2026, an estimated $28.6K.
  • Vir Biotechnology made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2254 holding.
  • Victory Capital Management first reported a position in Vir Biotechnology in Q1 2020 and has held it in 26 quarters since.
  • Victory Capital Management's Vir Biotechnology position peaked at $2.55M in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.